The investigational drug MDV3100 extended life by nearly five months, compared to placebo, in men with advanced prostate cancer, previously treated with chemotherapy.
The study also concluded that MDV3100 was generally well tolerated by patients and met all secondary endpoints.
Secondary endpoints in the study included radiographic progression-free survival (rPFS) and time to prostate-specific antigen (PSA) progression.
MDV3100, developed by Astellas Pharma and Medivation, is an oral androgen-receptor signalling inhibitor in clinical development for advanced prostate cancer.
A new European survey reveals 99% of oncologists and urologists feel there is a need for new treatments in advanced prostate cancer.